title: [Drug therapy and radiotherapy in Graves' orbitopathy].
abstract: Drug therapy and radiotherapy in Graves' orbitopathy (GO) aim mainly at the inherent soft tissue inflammation. A timely and sustained anti-inflammatory therapy not only alleviates the current symptoms but particularly intends to limit the degree of permanent alterations. It is indicated in active GO of moderate or higher severity. Pharmacologically, glucocorticoids and if appropriate other immunosuppressive agents, such as cyclosporine are given. Adverse effects can complicate the treatment. Retrobulbar irradiation is applied against diplopia due to eye muscle involvement during the active phase.
authors: Universitäts-Augenklinik Freiburg, Killianstr., Deutschland. flemming.beisse@uniklinik-freiburg.de
authors: F
authors: F
authors: Beisse
authors: W A
authors: WA
authors: Lagrèze
authors: M
authors: M
authors: Schmucker
references: J Clin Endocrinol Metab. 2005 Sep;90(9):5234-40
references: 15998777
references: Thyroid. 1997 Dec;7(6):885-9
references: 9459632
references: Eur J Endocrinol. 2007 Jan;156(1):33-40
references: 17218723
references: Eur J Clin Invest. 1986 Oct;16(5):415-22
references: 3100309
references: Clin Exp Immunol. 1996 Nov;106(2):197-202
references: 8918563
references: Acta Endocrinol (Copenh). 1990 Jan;122(1):8-12
references: 2305608
references: Ophthalmology. 2002 Jun;109(6):1183-7
references: 12045064
references: J Clin Endocrinol Metab. 2004 Jan;89(1):15-20
references: 14715820
references: J Clin Endocrinol Metab. 1983 Jun;56(6):1139-44
references: 6341388
references: N Engl J Med. 1992 Jun 25;326(26):1733-8
references: 1489388
references: Ophthalmologe. 2007 Sep;104(9):771-6
references: 17823804
references: Acta Endocrinol (Copenh). 1990 Jan;122(1):13-21
references: 2305603
references: Radiother Oncol. 2007 May;83(2):175-7
references: 17490769
references: Ann Intern Med. 1998 Oct 15;129(8):632-5
references: 9786811
references: Horm Metab Res. 2009 May;41(5):391-6
references: 19194836
references: N Engl J Med. 1989 Nov 16;321(20):1353-9
references: 2519530
references: Ophthalmology. 2001 Sep;108(9):1523-34
references: 11535445
references: Thyroid. 2007 Apr;17(4):357-62
references: 17465867
references: Eye (Lond). 2005 Dec;19(12):1286-9
references: 15550932
references: Br J Ophthalmol. 1998 Jul;82(7):754-7
references: 9924366
references: J Clin Endocrinol Metab. 2004 Dec;89(12):5910-5
references: 15579735
references: Lancet. 2000 Apr 29;355(9214):1505-9
references: 10801172
references: Lancet. 1993 Oct 16;342(8877):949-54
references: 8105213
references: Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):182-9
references: 12504052
references: Eur J Endocrinol. 2008 Mar;158(3):273-85
references: 18299459
references: Clin Endocrinol (Oxf). 2005 Sep;63(3):323-8
references: 16117821
references: Ophthalmology. 2004 Aug;111(8):1557-62
references: 15288988
references: Acta Endocrinol (Copenh). 1992 Jan;126(1):13-23
references: 1736548
references: Thyroid. 1997 Aug;7(4):579-85
references: 9292946
references: Eye (Lond). 1987;1 ( Pt 5):603-8
references: 3446541
references: Br J Ophthalmol. 2004 Nov;88(11):1380-6
references: 15489477